Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review

Abstract Background and Aims Management of Crohn’s disease and ulcerative colitis has typically relied upon treatment intensification driven by symptoms alone. However, a ‘treat-to-target’ management approach may help to address underlying inflammation, minimise disease activity at early stages of inflammatory bowel disease, limit progression, and improve long-term outcomes. Methods A systematic literature review was conducted to identify data relevant to a treat-to-target approach in inflammatory bowel disease, published between January 1, 2007 and May 15, 2017. Results Consistent with recommendations of the Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE] working group, studies have investigated factors influencing the achievement of both endoscopic and histological mucosal healing and patient-level outcomes in inflammatory bowel disease [IBD]. Histological healing and biomarker levels have also been shown to be modifiable outcomes. Although there is a lack of prospectively derived evidence validating mucosal healing as a treatment target, data are emerging to suggest that targeting mucosal healing or inflammation rather than symptoms may be cost-effective in some settings. The review highlighted several strategies that may support the implementation of a treat-to-target approach in IBD. The prospective randomised CALM study demonstrated how tight control [whereby treatment decisions are based on close monitoring of inflammatory biomarkers] leads to improvements in endoscopic and clinical outcomes. The review also considered the influence of coordinated care from a multidisciplinary team and patient engagement with improved adherence, as well as the role of therapeutic drug monitoring in inflammatory bowel disease management. Conclusions A treat-to-target strategy may impact on disease progression and improve outcomes in inflammatory bowel disease. Prospective studies including long-term data are required to ensure that the most appropriate targets and strategies are identified.

[1]  R. Shaoul,et al.  OP18 Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial , 2019, Journal of Crohn's and Colitis.

[2]  G. Rogler,et al.  OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM , 2019, Journal of Crohn's and Colitis.

[3]  S. Vermeire,et al.  Defining Endoscopic Remission in Ileocolonic Crohn's Disease: Let's Start from Scratch. , 2018, Journal of Crohn's & colitis.

[4]  J. Yamamoto-Furusho.  Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways , 2018, Current opinion in gastroenterology.

[5]  A. Gasbarrini,et al.  Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study , 2018, Journal of Crohn's & colitis.

[6]  D. Mould,et al.  Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System , 2018, Journal of clinical pharmacology.

[7]  D. Franchimont,et al.  Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. , 2018, Gastroenterology.

[8]  B. Kirkham,et al.  Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis , 2018, Rheumatology International.

[9]  M. Dubinsky,et al.  Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? , 2018, Gastroenterology.

[10]  D. Hommes,et al.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial , 2017, The Lancet.

[11]  P. Rutgeerts,et al.  Mucosal Healing and Long‐term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic‐Based vs Trough Concentration‐Based Dosing of Infliximab , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  P. Bossuyt,et al.  Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. , 2017, The lancet. Gastroenterology & hepatology.

[13]  A. Boonen,et al.  Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial , 2017, The Lancet.

[14]  Siddharth Singh,et al.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. , 2017, Gastroenterology.

[15]  L. Peyrin-Biroulet,et al.  Ulcerative colitis , 2017, The Lancet.

[16]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[17]  A. Deodhar,et al.  Treat to Target in Axial Spondyloarthritis: What Are the Issues? , 2017, Current Rheumatology Reports.

[18]  P. Rutgeerts,et al.  Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm , 2017 .

[19]  M. Abreu,et al.  Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease , 2017, Alimentary pharmacology & therapeutics.

[20]  Z. Zeng,et al.  Factors associated with the achievement of mucosal healing in Crohn’s disease: the benefit of endoscopic monitoring in treating to target , 2017, Therapeutic advances in gastroenterology.

[21]  R. Grouls,et al.  Short article: The effect of implementation of a treatment algorithm for infliximab on remission rates and drug costs in inflammatory bowel disease patients , 2017, European journal of gastroenterology & hepatology.

[22]  K. Taylor,et al.  P609 A treat-to-target approach via a virtual clinic amongst inflammatory bowel disease patients with secondary loss of response to anti-TNF therapy improves clinical outcomes. , 2017, Journal of Crohn's & colitis.

[23]  L. Peyrin-Biroulet,et al.  Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. , 2017, Gastroenterology.

[24]  E. Collantes-Estévez,et al.  Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry , 2016, Rheumatology International.

[25]  S. Basu,et al.  Comparative effectiveness and cost-effectiveness of target- versus benefit-based treatment of type 2 diabetes in low- and middle-income countries , 2017 .

[26]  M. Regueiro,et al.  Decreased Emergency Room Utilization and Hospitalizations, and Improved Quality of Life in the First Year of an Inflammatory Bowel Disease (IBD) Patient Centered Medical Home (PCMH): 579 , 2016 .

[27]  C. Steenholdt.  Personalized therapy with TNF-inhibitors in Crohn's disease: optimizing treatment outcomes by monitoring drug levels and anti-drug antibodies. , 2016, Danish medical journal.

[28]  M. Regueiro,et al.  Mo1863 Inflammatory Bowel Disease (IBD) Complexity and Quality of Life Correlates With Health Care Utilization in a New Patient Centered Medical Home (PCMH) , 2016 .

[29]  P. Rutgeerts,et al.  Sa1956 Post-Induction Adalimumab Concentration Threshold Is Associated With Short-Term Mucosal Healing in Patients With Ulcerative Colitis , 2016 .

[30]  M. Regueiro,et al.  Tu1946 Can We Phenotype IBD Patients Based on Financial Charges Over Time? Trajectory Modeling of Healthcare Utilization in a Large, Prospective IBD Cohort , 2016 .

[31]  D. Hommes,et al.  308 The Impact of a Value-Based Health Care in Inflammatory Bowel Diseases on Health Care Utilization , 2016 .

[32]  S. Hillary,et al.  P-012 YI Decisions to Dose Optimize Infliximab Using Pre-adjustment Therapeutic Drug Monitoring Result in Higher Trough Concentrations and Improved Endoscopic Outcomes , 2016 .

[33]  M. Silverberg,et al.  Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease. , 2016, Journal of Crohn's & colitis.

[34]  A. Bitton,et al.  Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial , 2015, The Lancet.

[35]  T. Murdoch,et al.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.

[36]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[37]  M. Cravo,et al.  New Trends in Inflammatory Bowel Disease , 2015, GE Portuguese journal of gastroenterology.

[38]  Steven J Brown,et al.  Crohn's disease management after intestinal resection: a randomised trial , 2015, The Lancet.

[39]  M. Skup,et al.  Sa1258 Comparison of Real-World Outcomes of Adalimumab (ADA) and Infliximab (IFX) for Patients With Ulcerative Colitis (UC) in the United States , 2015 .

[40]  L. Punzi,et al.  Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight , 2015, Lupus.

[41]  L. A. Christensen,et al.  Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab , 2015, Digestive Diseases and Sciences.

[42]  L. Öhman,et al.  Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: A prospective, randomized, controlled study , 2015, United European gastroenterology journal.

[43]  W. Sandborn,et al.  Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel Disease: Results from a Pilot Observational Study , 2014, Inflammatory bowel diseases.

[44]  M. Regueiro,et al.  Causes and Consequences of Chronic Abdominal Pain in Crohn’s Disease: A Five-Year Prospective Study: 1650 , 2014 .

[45]  W. Olson,et al.  Healthcare costs for Crohn’s disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence , 2014, Journal of medical economics.

[46]  M. Silverberg,et al.  Future directions in inflammatory bowel disease management. , 2014, Journal of Crohn's & colitis.

[47]  W. Sandborn,et al.  Endoscopic assessment and treating to target increase the likelihood of mucosal healing in patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[48]  H. Raspe,et al.  Inviting Patients with Inflammatory Bowel Disease to Active Involvement in Their Own Care: A Randomized Controlled Trial , 2014, Inflammatory bowel diseases.

[49]  R. Shamir,et al.  Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric ulcerative colitis , 2014, Gut.

[50]  M. Ingham,et al.  Health care costs by level of adherence for infliximab patients with crohn’s disease , 2014 .

[51]  B. Roth,et al.  Su1105 The Development and Evaluation of Coordinated Care Pathways for Inflammatory Bowel Diseases , 2014 .

[52]  G. David,et al.  Su1316 Effects of Patient Annual Adherence of Biologics on Healthcare Resource Utilization for Patients With Inflammatory Bowel Disease , 2014 .

[53]  M. Regueiro,et al.  Sa1227 Clinical Characteristics of Inflammatory Bowel Disease (IBD) Patients Who Call After Hours , 2014 .

[54]  W. Olson,et al.  Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy , 2014, Journal of medical economics.

[55]  R. Sahay,et al.  Treat-to-target trials in diabetes , 2014, Indian journal of endocrinology and metabolism.

[56]  D. Hommes,et al.  P333 The development of coordinated care pathways and feasibility testing in inflammatory bowel disease management , 2014 .

[57]  W. Sandborn,et al.  Feasibility of Endoscopic Assessment and Treating to Target to Achieve Mucosal Healing in Ulcerative Colitis , 2014, Inflammatory bowel diseases.

[58]  J. Rizzo,et al.  P-060 Cost Per Clinical Response, Clinical Remission, and Mucosal Healing of Golimumab Among Patients with Ulcerative Colitis: Results from PURSUIT-Maintenance , 2013 .

[59]  F. Guglielmi,et al.  Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[60]  M. Skup,et al.  Association between Adherence to Adalimumab Therapy and Health Care Costs for Patients with Crohnʼs Disease: Claims Database Analysis: 1708 , 2013 .

[61]  Kristin E. Burke,et al.  Impact of Non-adherence to Mesalamine on Relapse Rates and Healthcare Costs in Patients with Ulcerative Colitis in Clinical Practice: 1761 , 2013 .

[62]  Conveying medication benefits to ulcerative colitis patients and effects on patient attitudes regarding thresholds for adherence. , 2013, Journal of Crohn's & colitis.

[63]  L. A. Christensen,et al.  Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial , 2013, Gut.

[64]  W. Sandborn,et al.  A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[65]  D. Schwartz,et al.  Mo1376 Depression and the Cost of Outpatient Treatment of Crohn's Disease in an US Academic Medical Center , 2013 .

[66]  L. Peyrin-Biroulet,et al.  Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study , 2013, Inflammatory bowel diseases.

[67]  Tara K. Knight,et al.  Adherence to 5-ASA Therapy in Ulcerative Colitis: Budget Impact Analysis , 2013 .

[68]  M. Skup,et al.  P163 Quality of life for patients with deep remission vs. clinical remission and deep remission vs. absence of mucosal ulceration: 3-year data from CHARM/ADHERE , 2013 .

[69]  M. Kamm,et al.  Mucosal Healing in Crohn's Disease: A Systematic Review , 2013, Inflammatory bowel diseases.

[70]  A. Ananthakrishnan,et al.  Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn's Disease? A Decision Analysis , 2013, Inflammatory bowel diseases.

[71]  S. Vermeire,et al.  Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .

[72]  S. Saini,et al.  Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[73]  P. Hodgkins,et al.  Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis , 2012, BMC Gastroenterology.

[74]  P. Hodgkins,et al.  Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis , 2012, The Patient - Patient-Centered Outcomes Research.

[75]  M. Neurath,et al.  Mucosal healing in inflammatory bowel diseases: a systematic review , 2012, Gut.

[76]  L. Peyrin-Biroulet,et al.  Ulcerative colitis as a progressive disease: the forgotten evidence. , 2012, Inflammatory bowel diseases.

[77]  C. Carter,et al.  Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn’s disease , 2012, Patient preference and adherence.

[78]  C. Selinger,et al.  PMO-241 Conveying medication benefits to ulcerative colitis patients: what thresholds for adherence are applied? , 2012, Gut.

[79]  A. Ananthakrishnan,et al.  Mo1668 Mucosal Healing is a Cost-Effective Endpoint With Biologic Therapy in Crohns Disease - Results From a Decision Analysis , 2012 .

[80]  C. Beauchemin,et al.  PGI23 Economic Impact of Medication Adherence and Persistence in the Treatment of Ulcerative Colitis in Canada: Analyses with the Ramq Database , 2011 .

[81]  P. Rutgeerts,et al.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. , 2011, Gastroenterology.

[82]  C. Carter,et al.  Impact of infliximab adherence on Crohn’s disease-related healthcare utilization and inpatient costs , 2011, Advances in therapy.

[83]  P. Cook,et al.  Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. , 2010, Patient education and counseling.

[84]  B. Resman-Targoff,et al.  Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals. , 2010, The American journal of managed care.

[85]  Johan Burisch,et al.  E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided ‘Constant-care’ approach , 2010, Gut.

[86]  P. Rutgeerts,et al.  644 Early Mucosal Healing Status Predicts Long-Term Clinical Benefits for Adalimumab-Treated Patients With Moderate to Severe Crohn's Disease , 2010 .

[87]  C. O'Morain,et al.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. , 2010, Journal of Crohn's & colitis.

[88]  P. Rutgeerts,et al.  Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.

[89]  P. Hodgkins,et al.  Adherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis: impact on all-cause healthcare costs: P-0087. , 2009 .

[90]  J. Chao,et al.  Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients , 2009, Advances in therapy.

[91]  P. Rutgeerts,et al.  Mucosal healing predicts long‐term outcome of maintenance therapy with infliximab in Crohn's disease , 2009, Inflammatory bowel diseases.

[92]  T. Piche.  Impact de la chirurgie gynécologique sur le développement du syndrome de l’intestin irritable et des douleurs abdominales , 2008 .

[93]  F. Shaya,et al.  Medication Non-adherence is Associated with Increased Medical Health Care Costs , 2008, Digestive Diseases and Sciences.

[94]  M. Bala,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease , 2006 .

[95]  G. Porro,et al.  A rare cause of diuretic refractory ascites , 2005, Gut.

[96]  R. Wright,et al.  Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets , 1966, The American Journal of Digestive Diseases.

[97]  C. FordAlexander,et al.  ULCERATIVE colitis. , 1997, Journal of the American Medical Association.